No Association Between HLA-B*57:01 and Prevalence and/or Outcome of Progressive Multifocal Leukoencephalopathy in a French Nationwide Human Immunodeficiency Virus Cohort.

IF 1.5 4区医学 Q4 IMMUNOLOGY

AIDS research and human retroviruses Pub Date : 2024-04-01 Epub Date: 2023-10-18 DOI:10.1089/AID.2023.0050

Solène Secher, Maxime Hentzien, Lise Cuzin, Christine Jacomet, Laurent Hocqueloux, David Rey, Amélie Menard, Cédric Arvieux, François Raffi, Firouzé Bani-Sadr

引用次数: 0

Abstract

Among 34,351 patients living with human immunodeficiency virus with available HLA-B*57:01 included in the Dat'AIDS cohort, 194 patients (0.56%) had a history of progressive multifocal leukoencephalopathy (PML) and 1,746 (5.08%) were carriers of HLA-B*57:01. The frequency of HLA-B*57:01 was similar among patients with history of PML compared with patients without a history of PML (6.19% [95% confidence interval, CI 2.8%-9.6%] vs. 5.08% [95% CI 4.8%-5.3%]; p = .48). Among patients with PML, clinical and biological characteristics at PML diagnosis and the PML outcome were not different according to HLA-B*57:01 status.

查看原文本刊更多论文

在法国全国HIV队列中，HLA-B*57:01与进行性多灶性白质脑病的患病率和/或结果之间无相关性。

Dat’AIDS队列中有34351名可获得HLA-B*57:01的PLHIV患者，其中194名患者（0.56%）有进行性多灶性白质脑病（PML）病史，1746名患者（5.08%）为HLA-B*57:01携带者。有PML病史的患者与无PML病史患者的HLA-B*57:01频率相似（6.19%[95%CI 2.8%；9.6%]对5.08%[95%CI 4.8%；5.3%]；p=0.48）。在PML患者中，根据HLA-B*57:01状态，诊断PML的临床和生物学特征以及PML结果没有差异。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

AIDS research and human retroviruses 医学-病毒学

CiteScore

3.10

自引率

6.70%

发文量

201

审稿时长

3-6 weeks

期刊介绍： AIDS Research and Human Retroviruses was the very first AIDS publication in the field over 30 years ago, and today it is still the critical resource advancing research in retroviruses, including AIDS. The Journal provides the broadest coverage from molecular biology to clinical studies and outcomes research, focusing on developments in prevention science, novel therapeutics, and immune-restorative approaches. Cutting-edge papers on the latest progress and research advances through clinical trials and examination of targeted antiretroviral agents lead to improvements in translational medicine for optimal treatment outcomes. AIDS Research and Human Retroviruses coverage includes: HIV cure research HIV prevention science - Vaccine research - Systemic and Topical PreP Molecular and cell biology of HIV and SIV Developments in HIV pathogenesis and comorbidities Molecular biology, immunology, and epidemiology of HTLV Pharmacology of HIV therapy Social and behavioral science Rapid publication of emerging sequence information.